Provided by Tiger Fintech (Singapore) Pte. Ltd.

Milestone Pharmaceuticals Inc.

1.28
+0.02001.59%
Post-market: 1.28-0.0007-0.05%19:50 EDT
Volume:1.44M
Turnover:1.82M
Market Cap:68.29M
PE:-1.92
High:1.32
Open:1.28
Low:1.21
Close:1.26
Loading ...

TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty

Investing.com
·
02 Apr

Milestone Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
02 Apr

Milestone Pharmaceuticals Inc : H.c. Wainwright Cuts Target Price to $10 From $25

THOMSON REUTERS
·
01 Apr

BUZZ-Milestone Pharma falls after TD Cowen downgrades to "hold", removes PT

Reuters
·
01 Apr

HC Wainwright Adjusts Price Target on Milestone Pharmaceuticals to $10 From $25, Maintains Buy Rating

MT Newswires Live
·
01 Apr

Milestone Pharmaceuticals Inc : TD Cowen Cuts to Hold From Buy

THOMSON REUTERS
·
01 Apr

TD Cowen Downgrades Milestone Pharmaceuticals to Hold From Buy

MT Newswires Live
·
01 Apr

BUZZ-U.S. STOCKS ON THE MOVE-GameStop, Oxford Industries, Wolfspeed

Reuters
·
29 Mar

Milestone Pharmaceuticals Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
29 Mar

Dow Tumbles Over 500 Points; Abacus Global Management Shares Spike Higher

Benzinga
·
29 Mar

Piper Sandler Adjusts Price Target on Milestone Pharmaceuticals to $4 From $5, Maintains Overweight Rating

MT Newswires Live
·
28 Mar

Milestone Pharmaceuticals Shares Down 64.7% After FDA Declines to Approve Co's Heart Rhythm Nasal Spray

THOMSON REUTERS
·
28 Mar

BRIEF-FDA Issues Complete Response Letter For Etripamil For PSVT

Reuters
·
28 Mar

BUZZ-Milestone Pharma slumps after FDA declines to approve heart rhythm nasal spray

Reuters
·
28 Mar

Milestone Pharmaceuticals Shares Down 60% Premarket After FDA Declines to Approve Co's Heart Rhythm Nasal Spray

THOMSON REUTERS
·
28 Mar

FDA Rejects Milestone Pharmaceuticals' Etripamil Nasal Spray

Dow Jones
·
28 Mar

US FDA declines to approve Milestone Pharma's heart rhythm nasal spray

Reuters
·
28 Mar

Milestone Pharmaceuticals Inc - Inspection Required at Facility Performing Etripamil Release Testing

THOMSON REUTERS
·
28 Mar

Milestone Pharmaceuticals Inc - FDA Raises No Concerns on Etripamil Clinical Safety or Efficacy

THOMSON REUTERS
·
28 Mar

Milestone Pharmaceuticals Inc - Company to Submit Additional Info on Nitrosamine Impurities

THOMSON REUTERS
·
28 Mar